Subscribe to stay informed!
Malvern-based PhaseBio Pharmaceuticals has signed an exclusive licensing agreement valued up to $245 million with Alfasigma of Italy, writes John George for the Philadelphia…
Before we send you to this site, please subscribe to our daily newsletter.